A novel STING agonist, CDG^SF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDG^SF might be a site for covalent conjugation. Injection of CDG^SF generated an immunogenic (“hot”) tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDG^SF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDG^SF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.

中文翻译：

---

用于癌症免疫治疗的新型STING激动剂和SARS-CoV-2疫苗佐剂

合成了一种新的STING激动剂CDG ^SF，该化合物经硫代磷酸酯和氟同侧修饰。CDG ^SF中的硫代磷酸酯可能是共价结合的位点。注射CDG ^SF产生的免疫原性（“热”）肿瘤微环境比二硫代CDG更有效地抑制了黑色素瘤。特别是，使用CDG ^SF作为佐剂的SARS-CoV-2穗蛋白进行免疫接种可产生极高的抗体滴度和强大的T细胞反应，克服了氢氧化铝的缺点。这些结果首次突显了CDG ^SF在癌症免疫治疗中的治疗潜力，以及STING激动剂在SARS-CoV-2疫苗中的佐剂潜力。